Nasopharyngeal Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer
Conditions
Interventions
Population:Nil
Sponsors
Entopsis Asia
Eligibility
Sex/Gender
All
Age
20 Years to 85 Years
Inclusion criteria
Inclusion criteria: The first phase will be to examine urine samples obtained from patients with primary forms of cancer (untreated) and age matched controls ranging from 20-85. Depending on the screening criteria, patients who have been treated will be included in the screening procedure to determine if the platform can detect recurrence. As this platform is proposed for use with multiple forms of cancer, the inclusion criteria will be similar/identical among all patients. The cancers to be tested include 1) Lung and Bronchus; 2) Stomach; 3) Breast; 4) Esophagus; 5) Liver; 6) Colorectum; 7) Prostate; and 8) other cancers depending on disease prevalence and clinical access. 1. Patients must be >20 years of age; 2. Patients should have untreated, diagnosed forms of cancer (patients include newly diagnosed cancers and relapses greater than 6 months since the last intervention); 3. Patents must be mentally competent to make informed consent; 4. Patients must provide written informed consent and be willing to comply with the requirements of the protocol.
Exclusion criteria
Exclusion criteria: 1. Inability to provide informed consent; 2. Concurrent use or receipt within the previous 5 months of any chemo-therapeutic drugs or irradiation to treat the cancer, or treatment with corticosteroids at a dose > 40 mg/day (Note: doses <40 mg/day are permitted and not considered to be an exclusion factor); 3. Serious cardiovascular disease under current treatment; 4. Untreated type I and II diabetes; 5. Urine glucose levels above 1.0 mmol/L, which may be indicative of other underlying diseases; 6. Serious infections (hospitalization) within the prior 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Molecular binding profile on NuTECs of molecules present in patient urine.; | — |
Countries
China
Contacts
Public ContactKenneth R. Boheler
Hong Kong University
Outcome results
None listed